Get to know our clinical trials

Trial to evaluate the safety and antitumor activity of FS222, a bispecific antibody against CD137/PD-L1, in subjects with advanced malignancies.

THE GOAL IS TO DETERMINE WHETHER FS222 IS SAFE IN THE TREATMENT OF CANCER AND THE DEGREE TO WHICH A PERSON TOLERATES THE SIDE EFFECTS.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE 1, OPEN-LABEL, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF FS222, A BISPECIFIC ANTIBODY AGAINST CD137/PD-L1, IN SUBJECTS WITH ADVANCED MALIGNANCIES.
  • Code EudraCT: -
  • Protocol number: FS222-19101
  • Promoter: F-star Beta Limited
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.